Lipocine (NASDAQ:LPCN) Stock Price Crosses Above Fifty Day Moving Average – Here’s What Happened

Shares of Lipocine Inc. (NASDAQ:LPCN) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.31 and traded as high as $2.52. Lipocine shares last traded at $2.44, with a volume of 14,702 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts have commented on LPCN shares. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. Wall Street Zen cut shares of Lipocine from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Weiss Ratings lowered shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $15.00.

Lipocine Trading Down 1.2%

The business has a 50-day moving average price of $2.31 and a two-hundred day moving average price of $5.45. The firm has a market capitalization of $20.11 million, a price-to-earnings ratio of -1.30 and a beta of 0.44.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%.The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.16 million. On average, equities research analysts predict that Lipocine Inc. will post -1.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lipocine

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new position in shares of Lipocine during the fourth quarter worth about $85,000. Citadel Advisors LLC acquired a new stake in shares of Lipocine in the 3rd quarter worth about $41,000. Dimensional Fund Advisors LP lifted its position in Lipocine by 57.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock valued at $153,000 after purchasing an additional 6,982 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in Lipocine in the 1st quarter valued at about $185,000. Finally, Renaissance Technologies LLC boosted its stake in Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,300 shares during the period. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.